Youtor
Descubre ENDOCARE RADIANCE C Ferulic Edafence Serum
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=nd80rBjdMn8
An international Phase II clinical trial led by researchers at MD Anderson Cancer Center found that treatment with the FGFR inhibitor erdafitinib resulted in a 40% response rate for patients with metastatic bladder cancers marked by mutations in the FGFR3 gene. • • Arlene Siefker-Radtke, M.D., principal investigator on the trial and professor of Genitourinary Medical Oncology at MD Anderson, discusses the importance of this clinical trial for patients with bladder and other urothelial cancers. • • Request an appointment at MD Anderson by calling 1-877-632-6789 or online: https://my.mdanderson.org/RequestAppo....
#############################
